Detail akcie Forte Bioscienc Rg online

Business Summary: Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Forte Biosciences Inc revenues was not reported. Net loss increased 57% to $44.6M. Higher net loss reflects Research and development - Balancing val increase from $14.8M to $34.9M (expense), Stock-based Compensation in SGA increase from $1.5M to $3.4M (expense), Stock-based Compensation in R&D increase of 37% to $1.2M (expense).